Impressive Vespro Somatoplex/med CFS study

[Guest guest]

A doc who treats CFS patients in Houston has released data on 200

patients using Vespro's GHR products.

Not to promote Vespro, but the numbers even if they are viewed as

somewhat marketing material appear fairly significant.

vespro blurb:

NEW HOPE FOR CFS PATIENTS!

A CLINICAL TRIAL OF SOMATOPLEX

VESPRO GHS GROWTH HORMONE SECRETAGOGUE

IN PERSONS WITH CHRONIC FATIGUE SYNDROME

Salvato, P., , C., Bayou City Medical Center Hospital,

Houston, Texas, U.S.A.

Objective: To determine if a growth hormone secretagogue called

SomatoPlex (VesPro GHS Growth Hormone) was safe and efficacious in

patients with CDC define Chronic Fatigue Syndrome (CFS).

Methods: Body cell mass measured by BIA (BCM), natural killer number

(NK#), and Insulin growth factor-1 (IgF-1) levels were evaluated in

200 CFS patients. These measures were assessed at study initiation

and every month for three months. Subjective measures of symptoms,

cognitive function, activities of daily living and sleep disturbance

were also assessed monthly for three months.

Results:

Objective

BCM: 126 (63%) of the patients had increase in BCM of 1 lb or more;

103 (82%) lost weight due to decrease in fat body mass; 23 (18%)

gained from 5-11 lbs.;

IgF-1: 118 (59%) patients had increase in their IgF-1 level of 20% or

more NK#: 129 (65%) had increase of their NK# of 30% or more;

Subjective

Sleep: 158 (79%) had marked improvement in their sleep;

Cognitive: 156 (78%) had marked improvement in cognitive function;

Muscle Pain: 104 (52%) had improvement in muscle pain;

Fatigue: 135 (68%) had improvement in fatigue;

Side effects:

56 (28%) had transient muscle and joint pain during initiation of

therapy;

61 (31%) of the patients had mild edema;

Conclusion:

An oral secretagogue, SomatoPlex, has been found to be a safe and

efficacious therapy, capable of improving many of the clinical signs

and symptoms associated with the Chronic Fatigue Syndrome.

Clinically, the efficacy of SomatoPlex has been verified through IgF-

1 measurements and patient assessment, as well as improvement in

immune function and body cell mass. It is of interest to note that

even in patients who did not raise IgF-1 levels, significant

improvement in sleep and cognition were still noted. This product

deserves further study in patients with Chronic Fatigue Syndrome.